Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FDPS | P14324 | 3/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1321198 | 1.00 | LMNA (0.39) | LMNADNM1TSHRTHRBCA2 | |
| SCHEMBL29083534 | 1.00 | LMNA (0.39) | LMNADNM1TSHRTHRBCA2 | |
| SCHEMBL4556906 | 0.98 | OPRM1 (0.39) | LMNADNM1TSHRTHRBCA2 | |
| SCHEMBL4451765 | 0.90 | DNM1 (0.36) | LMNADNM1TSHRCA2FDPS | |
| SCHEMBL7901136 | 0.86 | LMNA (0.39) | LMNADNM1TSHRTHRBCA2 | |
| SCHEMBL11686625 | 0.86 | LMNA (0.39) | LMNADNM1TSHRTHRBCA2 | |
| SCHEMBL28471373 | 0.83 | OPRM1 (0.39) | LMNADNM1TSHRTHRBCA2 | |
| SCHEMBL30549091 | 0.82 | LMNA (0.37) | LMNADNM1TSHRTHRBCA2 | |
| SCHEMBL9750933 | 0.82 | LMNA (0.37) | LMNADNM1TSHRTHRBCA2 | |
| SCHEMBL31405411 | 0.82 | LMNA (0.41) | LMNADNM1CA2SMPD1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010144080-A1 | IMPROVED CATALYST FLOW | BASF CATALYSTS LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| EP-1989194-B1 | CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-7638585-B2 | Catalyst flow | BASF CATALYSTS, LLC (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090286942-A1 | CATALYST FLOW | BASF CATALYSTS LLC (US) | 2009-11-19 | — | — | US | disclosed |
| US-7538123-B2 | Indole derivative having piperidine ring | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20090099207-A1 | Cyclic sulfones useful as BACE inhibitors | RUEEGER HEINRICH | 2009-04-16 | — | — | US | disclosed |
| US-20070219179-A1 | Indole Derivative Having Piperidine Ring | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1757599-A1 | INDOLE DERIVATIVES HAVING PIPERIDINE RINGS | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7135531-B2 | Spherical catalyst for olefin polymerization | BASF CATALYSTS LLC (US) | 2006-11-14 | — | — | US | disclosed |
| US-20050256103-A1 | Indole derivative having piperidine ring | EISAI CO., LTD. | 2005-11-17 | — | — | US | disclosed |
| US-20050176900-A1 | Spherical catalyst for olefin polymerization | ENGELHARD CORPORATION | 2005-08-11 | — | — | US | disclosed |
| EP-0284005-B1 | METHOD OF PRODUCTION OF POLYOLEFINS | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1991-12-18 | — | — | EP | disclosed |
| US-4981930-A | POLYMERIZATION CATALYSTS | IDEMITSU PETROCHEMICAL COMPANY LIMITED (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0284005-A2 | Method of production of polyolefins | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099207-A1 | Cyclic sulfones useful as BACE inhibitors | BACE1, BACE2, APP | LMNA 3244/4885DNM1 526/4885TSHR 4711/4885 |
| US-20070219179-A1 | Indole Derivative Having Piperidine Ring | HTR5A, HTR2C, HTR1A | LMNA 3625/4885DNM1 3027/4885TSHR 365/4885 |
| US-20050256103-A1 | Indole derivative having piperidine ring | HTR5A, HTR2C, HTR1A | LMNA 4157/4885DNM1 2398/4885TSHR 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.